Key result
PDE4 activator MR-L2 cuts catecholamine-induced arrhythmic events by ~64 percentage points in Takotsubo cardiomyocytes.
Why the study?
Atrial fibrillation is common and associated with increased mortality in Takotsubo Syndrome, yet the underlying arrhythmic mechanisms, genetic variability, and personalised therapy remained unclear.
Does the PDE4 activator MR-L2 restore Ca2+ handling and prevent catecholamine-induced arrhythmias more effectively than metoprolol in patient-specific atrial iPSC-derived cardiomyocytes from Takotsubo Syndrome?
Does the PDE4 activator MR-L2 restore Ca2+ handling and prevent catecholamine-induced arrhythmias more effectively than metoprolol in patient-specific atrial iPSC-derived cardiomyocytes from Takotsubo Syndrome?
Absolute Event Rate: 3% vs 67%
This patient-specific iPSC-CM study identifies genetic variants in AHNAK and reduced PDE4 activity as key drivers of catecholamine-induced atrial arrhythmogenesis in Takotsubo Syndrome, demonstrating that pharmacological PDE4 activation with MR-L2 suppresses cellular arrhythmias more effectively than metoprolol.
Supports PDE4 activation as antiarrhythmic target in Takotsubo; leaves open clinical translation beyond iPSC models.
Takotsubo Syndrome (TTS) is an acute, potentially life-threatening condition often complicated by ventricular dysfunction and arrhythmias. Atrial fibrillation (AF) is common in TTS patients and associated with increased mortality. However, the arrhythmic mechanisms, genetic variability underlying TTS, and personalised therapy remain unclear. We generated induced pluripotent stem cell-derived atrial and ventricular cardiomyocytes (iPSC-CMs) from TTS patients and provoked TTS-like events by isoprenaline (Iso) stimulation. Compared with controls, atrial TTS iPSC-CMs exhibited enhanced diastolic sarcoplasmic reticulum (SR) Ca²⁺ leak and increased arrhythmogenic potential following Iso exposure. Iso-induced stress further increased systolic Ca²⁺ transient amplitude and reduced phosphodiesterase 4 (PDE4) activity in TTS iPSC-CMs. Under baseline conditions, atrial TTS iPSC-CMs demonstrated unchanged Ca 2+ transient amplitude, reduced diastolic Ca 2+ , elevated SERCA2 activity with faster Ca²⁺ decay compared to controls, which could be explained by increased phosphorylation of PKA-specific phospholamban S16. In contrast, ventricular TTS-iPSC-CM showed increased L-Type Ca 2+ current density, but reduced Ca 2+ transient amplitude with increased resting Ca 2+ leak and reduced PDE4 activity post-Iso-exposure. In atrial TTS iPSC-CMs, the PDE4 activator MR-L2 restored PDE4 activity, normalised several defects in Ca²⁺ handling and prevented arrhythmias more efficiently than the β-blocker metoprolol. Genetic analyses identified variants in the Ca²⁺ handling genes AHNAK and CASQ2 in TTS. Using CRISPR/Cas9, we generated isogenic rescue and mutation-insertion lines, confirming a causal role of p.P5390T in catecholamine-induced arrhythmogenic phenotypes in atrial TTS iPSC-CMs. Our findings support a mechanistic link between genetic predisposition to an excessive catecholaminergic stress response, dysregulated PDE/cAMP signalling, and atrial arrhythmogenesis in TTS-CMs, identifying PDE4 as a potential therapeutic target in this critical condition.
No takes yet. Share an insight, caveat, or question.
Brand et al. (2026) studied Takotsubo Syndrome (TTS) (n=6). MR-L2 (PDE4 activator) vs. Isoprenaline-stressed untreated TTS iPSC-CMs and metoprolol was evaluated on Fraction of arrhythmic cells in isoprenaline-stressed atrial TTS iPSC-derived cardiomyocytes. The PDE4 activator MR-L2 reduced catecholamine-induced arrhythmic events from 67% to 3% and decreased diastolic SR Ca2+ leak by 3-fold in atrial Takotsubo Syndrome iPSC-derived cardiomyocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: